Theriva Biologics, Inc.
TOVX
$0.31
-$0.01-3.58%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.83M | 6.39M | 6.70M | 6.87M | 6.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.37M | 17.94M | 18.73M | 20.21M | 21.58M |
| Operating Income | -26.37M | -17.94M | -18.73M | -20.21M | -21.58M |
| Income Before Tax | -29.56M | -24.81M | -25.65M | -27.12M | -23.22M |
| Income Tax Expenses | -- | -- | -- | -424.00K | -951.00K |
| Earnings from Continuing Operations | -29.56 | -24.81 | -25.65 | -26.69 | -22.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.56M | -24.81M | -25.65M | -26.69M | -22.27M |
| EBIT | -26.37M | -17.94M | -18.73M | -20.21M | -21.58M |
| EBITDA | -26.26M | -17.81M | -18.59M | -20.06M | -21.43M |
| EPS Basic | -11.89 | -20.68 | -26.65 | -33.09 | -31.13 |
| Normalized Basic EPS | -5.49 | -7.93 | -11.48 | -15.63 | -18.24 |
| EPS Diluted | -11.89 | -20.68 | -26.65 | -33.09 | -31.13 |
| Normalized Diluted EPS | -5.49 | -7.93 | -11.48 | -15.63 | -18.24 |
| Average Basic Shares Outstanding | 13.46M | 7.49M | 5.39M | 3.28M | 2.83M |
| Average Diluted Shares Outstanding | 13.46M | 7.49M | 5.39M | 3.28M | 2.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |